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Nature and extent of deprescribing during medicines optimisation reviews in care homes 
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ABSTRACT 
 
Objectives 
To evaluate and understand the nature and extent of deprescribing when medicines are optimised in 
a pharmacist-led multidisciplinary clinic with care homes. 
 
Methods 
A retrospective analysis was carried out on a quality improvement project where 422 care home 
residents in 20 care homes received a medicines optimisation review with a pharmacist and other 
members of the healthcare team (general medical practitioner, care home nurse).  Data on number, 
type and cost of medicines were collected.  Statistical analysis was performed to test for differences 
between pharmacist-only review and the pharmacist plus general practitioner (GP), and to identify 
any correlation between the original number of medicines and the number of medicines stopped. 
 
Results 
Of the 422 patients reviewed, 298 (70.6%) had at least one medicine stopped with 704 medicines 
being stopped. This represented 19.5% of the medicines originally prescribed (3602 medicines).  
There was no statistically significant difference between pharmacist-only and pharmacist-plus-GP in 
terms of stopping medicines.  The main groups of medicines stopped were laxatives, skin products 
and bone protection.  There was weak correlation between the original number of medicines 
prescribed and the number stopped. 
 
Conclusion 
This study has shown that medicines optimisation reviews can lead to a reduction in polypharmacy 
for care home residents through a deprescribing process. Patients’ medicine regimens were 
simplified and optimised whilst making financial significant savings for the NHS. 
 
Key Messages 
What is already known on this subject  
• Polypharmacy can lead to adverse events 
• Deprescribing medicines can improve quality and reduce healthcare costs 
• Deprescribing is difficult with few tools or guidelines to support practitioners 
 
What this study adds  
• Structured medicines optimisation reviews allow medicines to be deprescribed safely in a 
care home setting  
• Most medicines stopped had no indication or purpose 
• Medicines can be stopped across a wide range of therapeutic areas 
 
  
INTRODUCTION 
While polypharmacy can be essential to improve the quality of life for many patients, it can also lead 
to increased risks of adverse drug reactions, drug interactions and reduced medicines adherence. 
There is a body of evidence to suggest that potentially inappropriate prescribing (PIP) and 
polypharmacy is common in elderly populations residing in nursing home settings.(1, 2) Targeting 
and reducing such prescribing should be a key priority for clinicians, not solely to reduce negative 
clinical outcomes and the adverse effects of inappropriate drugs, but also to reduce the financial 
burden upon healthcare providers.  
 
To minimise these effects, a key component of medicines optimisation is the avoidance of 
unnecessary or harmful medicines, with studies showing that input from a multidisciplinary team 
(MDT) or a pharmacist-led review can facilitate the reduction of polypharmacy.(3-5)  
 
Deprescribing is a term frequently used to describe the planned reduction and stopping of 
medication.(6-8)  It is an important part of the prescribing process as medicines should be regularly 
reviewed and when a medicine stops benefiting a patient it should stopped. 
 
Guidance for withdrawing medication, as with starting treatments, will help to ensure that 
deprescribing becomes part of a prescribing process.  However, there is little support for 
practitioners who wish to stop medicines. Solutions to support deprescribing include tools which 
identify potentially inappropriate medication, such as the STOPP-START tool(9) and Beers 
criteria.(10) Although studies have demonstrated their impact on reducing inappropriate medicines, 
they are neither patient-centred nor transferrable to all patients. All patients should receive a 
regular benefit-harm assessment of their medication as circumstances change, bearing in mind age 
and comorbidities, to identify medicines which are providing little benefit. Stopping criteria based on 
therapeutic failure is typically left to clinical judgement. 
 
Deprescribing to support patient outcomes. Scott et al JAMA 2015; Gnjidic et al BMJ 2014 
 
Rational medication use should involve patients in decision-making about their medication and 
consider when medication may no longer be beneﬁcial. Prescribers must acknowledge and 
overcome uncertainties inherent in deprescribing of medication.(11) Barriers to patient-centred 
deprescribing include disagreement with the appropriateness of cessation, fear of consequences of 
cessation, absence of a process for cessation and negative influences on patients’ decisions to cease 
medication.(12) 
 
There are emerging studies on the potential benefits of deprescribing. For instance, Todd et al and 
Lindsay et al showed the potential to stop medicines in patients with lung cancer.(13, 14)  
 
 
This study aimed to investigate whether medicines review led by pharmacists would lead to 
deprescribing of medications.  Secondary aims were to assess the reasons for and impact of 
deprescribing. 
 
METHODS 
This was a retrospective analysis of the Shine Medication Optimisation Project; a quality 
improvement project where care home residents were reviewed and medicines optimised within a 
shared decision-making framework.(15)  The project used a patient centred approach where the 
answer to three questions (Northumbria 3Q) were discussed with residents in 20 care homes and 
joint decisions made.(15)  The three questions were: (i) is there an indication for the medication (i.e. 
where the medicine is neither treating nor preventing any disease nor alleviating symptoms)? (ii) is 
the indication appropriate when co-morbidity and current clinical situation is taken into 
consideration (e.g. bone protection treatments for bed-bound residents)? and (iii) is the medication 
safe?(15)  Clinical judgement backed up by a review of the clinical notes was used to assess 
appropriatness of medicine.  The final decision to stop or continue the medicines was made jointly 
with the patient or their advocate. 
 
All carehomes across a Clinical Commissioning Group (CCG) were invited to participate, with 
residents based in 20 homes receiving medication optimisation reviews.  As this was a quality 
improvement project, care homes were not randomly selected, but selected based by their 
willingness and that of their general medical practice to participate in the project.  Care homes 
across two CCGs in North East England were invited to participate.  Of the 20 care homes, 15 were 
mixed (nursing, EMI (elderly & mentally infirm) and residential) with three being residential and two 
nursing only. 
 
The review process involved a pharmacist-led review of medicines, where each medicine was 
questioned using the Northumbria 3Q approach.  This was followed by a multidisciplinary team 
(MDT) meeting involving pharmacists and care home nurses, with other professionals (e.g. general 
medical practitioners and mental health professionals) joining when required. Whenever possible, 
the final decisions were made with patients and their families. After the review, the project database 
was updated to show medicines taken prior to review, medicines stopped, started or changed and 
any other interventions made.   
 
In total, 422 residents were reviewed, with pharmacists and other professionals making 1346 
interventions jointly with care home residents.(15) The most common intervention was to stop 
medicines, accounting for 704 medicines stopped in 298 (70.6%) of patients.(15) 
 
The project database was analysed and data presented descriptively. The number and type of 
medicines stopped as well as the cost saving associated with deprescribing was reported.  The 
reasons why medicines were stopped were collated and these data were extracted from the project 
database for this study.  All medicines prices were calculated using the National Health Service (NHS) 
Drug Tariff and savings annualised, thus making the assumption that the medicine would have been 
taken for another 12 months after deprescribing. The Kings Fund predicts a 65% increase in patients 
needing advanced care by 2030.(16) The Nuffield Trust have estimated a median length of stay of 18 
months for people admitted to permanent residential care.(17) This is consistent with a 
BUPA 2012 survey of its care homes which demonstrated a median length of stay of 20 months.(18) 
 
In the project there were two models of working: pharmacists working independently of general 
practitioners, making prescribing decisions, including decisions to stop medicines; and prescribing 
decisions made jointly by pharmacists and general practitioners. Both models of working were part 
of a shared decision-making approach with residents or their families   
 
 
IBM® SPSS® Statistics (Version 21) was used to determine statistical differences, on the basis of a t-
test, between number of medicines stopped, between pharmacists working independently or with 
general medical practioners. To understand whether the deprescribing was affected by the original 
number of medicines prescribed to the patient a Pearson’s correlation was performed. 
 
This project was funded by the Health Foundation as part of the Shine 2012 programme.  This was 
run as a quality improvement project. Advice on ethical approval was sought from the Trust’s 
research and development lead.  It was agreed that ethical approval for the QI project and this 
subsequent analysis was not required. 
 
 
RESULTS 
422 residents were reviewed in 20 care homes (2 residential, 3 nursing and 15 mixed) between 
January 2013 and March 2014.  The average age of the cohort was 85.5y with 77.7% being female.  
The 422 residents were collectively taking 3602 medicines prior to the review, with 704 (19.5%) 
stopped in 298 residents during the review. The 298 residents who had medicines stopped were 
taking a total of 1346 medicines prior to review, with 704 (52.3%) of their medicines stopped.  The 
mean number of medicines stopped was 2.36 (SD 1.53) ranging from 0 to 9.  There was no statistical 
difference between numbers of medicine stopped by pharmacist prescribers (53.4% stopped) and 
numbers stopped (51.9%)  where general practitioners were involved (p=0.9702; 95% Confidence 
Interval: -0.39 to 0.38). 
 
Of the 704 medicines that were stopped, 142 were acute medicines and 562 were regular repeat 
medicines.  The primary reason for stopping medicines was that the medicine had no current 
indications (n=400; 56.8%) with 15.9%, 8.7%, 6.5% of deprescribing accounted for by, respectively, 
patient choice, the indication no longer being appropriate and safety reasons (Table 1). 
 
Table 1: Reasons why medicines were deprescribed 
Reason 
n 
medicines 
No indication 400 
Patient refusing medicine 112 
Indication not appropriate 61 
Safety 46 
Ineffective treatment 29 
Therapeutic Switch 17 
Duplication 12 
Other 27 
 
Medicines were stopped from all but three (malignant disease, immunology, and anaesthesia) 
sections of the British National Formulary. The most common groups of medicines deprescribed 
were laxatives (14.5%), skin products (8.4%), bone protection drugs (7%), acid regulating medicines 
(5.4%), antidepressants (4.7%), antihypertensives (4.3%) and lipid regulating medicines (4.3%) (Table 
3).  All medicines were stopped after involving residents and/or their families/advocates and taking 
their views into account.(15) 
 
Table 2: Common Groups of medicines deprescribed 
Type of drug Number % 
Laxatives 102 14.4 
Skin 59 8.4 
Bone Protection 49 7.0 
Acid regulating 38 5.4 
Antidepressants 33 4.7 
Hypertension 30 4.3 
Lipid regulation 30 4.3 
Others 363 51.5 
 
Many residents were prescribed a number of laxatives and the main drugs stopped were sodium 
docusate, macrogols and senna.  Bone protection medicines were all stopped because the resident 
was immobile (bed or chair bound) and at low risk of falls.  Many acid regulating drugs were no 
longer indicated (e.g. they were originally prescribed short term).  Antidepressants were 
deprescribed after consultation with resident, family and care home staff, sometimes also involving 
the relevant old age psychiatrist.  Hypertension medicines were only stopped where blood pressure 
was low or where there was a falls risk.  Lipid regulating medicines were mainly statins and were 
stopped after discussing their benefits and risks. 
 
All residents were monitored following any deprescribing and adverse events documented.  Only 
seven events (0.99%) were reported (Table 4).  The events were all minor and were reversed.  In one 
case, the patient became very weepy and tearful and the antidepressant (citalopram) was restarted.  
For four situations another medicine was started and the for the remaining two cases the medicine 
was started at a lower dose and monitoring was put into place. 
 
Table 3: Adverse events caused by deprescribing 
Event Cause Action 
Hypertensive (BP increased from 
130/80 to 158/80) 
Stopped 
bendroflumethiazide 
Monitor but leave off 
bendroflumethiazide 
Swelling legs Furosemide stopped Restarted but lower dose 
UTI Stopped trimethoprim treated and restarted 
prophylaxis 
BP 170/90 Amlodipine stopped (leg 
swelling) 
Start another hypertensive 
Weepy and tearful Stopped citalopram Restarted 
BM raised Stopped metformin Increase insulin 
GI - heartburn Stopped omeprazole Start  Lansoprazole 
 
The relationship between the number of medicines originally prescribed and number stopped was 
investigated using the Pearson’s correlation.  There was a weak positive relationship (r=0.333) which 
tailed off at 15 medicines originally prescribed. 
 
The assumption that each medicines would have been taken for another year was made when 
measuring the financial impact of deprescribing.  The medicines stopped amounted to £65,471 in 
terms of annualised savings.(15) 
 
DISCUSSION 
This study aimed to uncover the extent to which deprescribing could be conducted using a 
structured medication review within a MDT across 20 nursing homes in North East England.  Overall, 
1 in 20 medicines were stopped for every resident reviewed, with medicines being stopped in over 
two thirds of residents reviewed. With this ageing cohort, it is expected that there will be multiple 
co-morbidities and complex clinical presentations. It is, perhaps, not surprising that patients were 
prescribed an average of 9 medicines per resident prior to the medication reviews, yet this was 
reduced to an average of 7 medicines per person reviewed. 
 
Using two models of delivery for the service (pharmacist actioning decisions or pharmacist and 
general practitioner actioning decisions); there was no statistical difference in number of medicines 
deprescribed between the two methods. 
 
The main reason for stopping a medicine was when there was no current indication for the drug, 
followed by discontinuation on patient request. Other studies have found reasons for polypharmacy 
include the prescribing of duplicate medicines or the use of medicines no longer required which 
have yet to be removed from the repeat prescription.(19, 20) 
 
It was determined that there was only a weak positive relationship between the number of drugs 
suitable for discontinuation and the number of medicines taken prior to review. It can be concluded 
that it is not always necessary for patients to be taking large numbers of drugs to allow successful 
deprescribing to take place. 
 
There were nine adverse effects reported thought to be related to the cessation of a medicine 
during the study. None of the effects was serious and they were appropriately rectified by either 
monitoring the patient or re-instating the drug or an alternative. Through careful review using a 
multi-disciplinary approach, deprescribing can be performed effectively and safely. It is also clear 
that appropriate monitoring post-cessation is important to pick up any untoward effects that may 
occur. One of the limitations in attributing adverse effects to the cessation of a drug is that is it 
difficult to be certain of causation, bearing in mind the complexity of co-morbidities in the older 
population.  
 
To assess the financial impact, we assumed that residents would have taken medicines for at least 
another 12 months after it was deprescribed.  This is an underestimate as on average care home 
residents live for 18 months.(17)  It is a limitation of this study that actual lifespan was not 
measured.  Significant savings were shown from the primary care medicines budget (in excess of 
£60,000), which if scaled up could potentially reduce healthcare expenditure globally. There is also 
the possibility that sequelae from inappropriate prescribing may have increased healthcare costs 
further, had the drug not been stopped. It is impossible to predict the extent to which deprescribing 
may have prevented such complications of therapy. 
 
A further limitation of this study is that the impact of deprescribing on pharmaceutical waste was 
not measured. Further research into financial savings from reduced medicines waste would be 
useful. The longer term clinical outcomes for the patients undergoing deprescribing also remain 
uncertain. In the short term, patients tolerated the reduction in medication reasonably well, but 
data collection was not continued over an extended period which would have allowed any longer 
term complications to be detected.  
 
Another limitation of the study was the measure of intervention quality. Pharmacist and physician 
interventions were not externally validated by an independent clinician for standardisation. It can be 
assumed that approaches to deprescribing will depend on the individual clinician, based upon their 
experience and profession. 
 
In conclusion, this study has shown that structured reviews with patient involvement and a multi-
disciplinary approach can lead to a reduction in polypharmacy for care home residents through a 
deprescribing process. Patients’ medicine regimens were simplified and optimised whilst making 
financially significant savings for the NHS. 
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